16144-91-5Relevant academic research and scientific papers
Synthesis and supramolecular structures of molecular clips
Kl?rner, Frank-Gerrit,Panitzky, Jens,Bl?ser, Dieter,Boese, Roland
, p. 3673 - 3687 (2001)
The syntheses of the novel dimethylene-bridged clips 4a-e and 5b are reported. They selectively bind electron-deficient neutral and cationic aromatic substrates comparable to the tetramethylene-bridged tweezers 1 and 2. The geometry of the noncovalently bound complexes with 4b-d as receptors derived from the single-crystal structure analyses is, however, different from that of the complexes with 2 as receptor. In clip complexes the plane of the included aromatic substrate molecule is orientated almost parallel to the naphthalene side-walls of the clip, whereas in the tweezer complex the substrate is orientated parallel to the central arene spacer-unit. TCNB 19 as substrate is placed inside the cavity of the hydroquinone clip 4c in solution as well as in the cocrystal. In contrast it was found for the cocrystal with the diacetate clip 4b that the TCNB 19, is placed between the naphthalene side-wall of two different clip molecules whereas in solution 19 is included into the cavity of 4b. Finally, 19 forms a (1:2) complex with dinaphthonorbornadiene 20 in solution as well as in the crystalline state. The findings reported here are instructive for the understanding of the weak noncovalent binding forces particularly the arene-arene interaction.
Singlet Oxygenation of a Conjugated Diallene: Attempt to Prepare a Stable Divinyl Peroxide
Mebane, Robert C.,Schuster, Gary B.
, p. 810 - 812 (1983)
A conjugated diallene, 2,3-divinylidenebicycloheptane, was prepared and isolated.Photosensitized oxygenation of this allene leads to two isolated oxygenated products in 50percent yield.Detection of these products is interpreted to implicate an unstable cyclic divinyl peroxide intermediate.Attempts to detect this intermediate by low temperature NMR spectroscopy and by chemiluminescence were unsuccessful.The instability of this compound is attributed to the destabilizing lone-pair interaction of the peroxide oxygen atoms.
Development of a Synthesis Process for a Novel HCV NS5A Inhibitor, Emitasvir
An, Delie,Dong, Wanrong,Fang, Qinghong,Feng, Yahui,Huang, Enhuo,Liu, Haiwang,Peng, Zhihong,Xiang, Xuwen,Xie, Hongming,Zhang, Yingjun
supporting information, p. 838 - 848 (2021/05/07)
A new approach to the synthesis of Emitasvir (DAG181), a small molecule hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor, is described. Enantioselective enzymatic desymmetrization with hydrolases in the synthetical approach can significantly avoid the loss of chiral raw materials in the resolution process. The synthesis route is further optimized and scaled-up to establish a new process that is applied to the preparation of kilogram scales of target active pharmaceutical ingredients (APIs). Compared with our initial process, the overall yield of target API was dramatically improved from 17 to 40%.
BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
-
Paragraph 0218; 0258; 0259, (2017/04/11)
Provided herein is a bridged bring compound of formula (I) or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore provided herein are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions thereof in the treatment of HCV infection or hepatitis C.
Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof
-
, (2015/03/28)
Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.
BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
-
, (2015/08/06)
Provided herein is a bridged bring compound of formula (I) or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore provided herein are pharmaceutical compositions containing the compounds and the method of using the compounds or harmaceutical com ositions thereof in the treatment of HCV infection or he atitis C.
BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS AND PHARMACEUTICAL APPLICATIONS THEREOF
-
, (2014/02/16)
Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.
